We have located links that may give you full text access.
Presbyopic Correction Using Monocular Bi-aspheric Ablation Profile (PresbyMAX) in Hyperopic Eyes: 1-Year Outcomes.
Journal of Refractive Surgery 2017 January 2
PURPOSE: To present the 1-year outcomes of combining monocular bi-aspheric ablation profile and contralateral monofocal LASIK in hyperopic patients with presbyopia.
METHODS: In this retrospective case series, 36 consecutive patients (72 eyes) who underwent simultaneous bi-aspheric ablation (PresbyMAX: SCHWIND Eye-Tech-Solutions GmbH and Co KG, Kleinostheim, Germany) in the non-dominant eye and monofocal regular LASIK in the dominant eye for correction of hyperopia and presbyopia were reviewed for 1 year. Binocular uncorrected distance (UDVA), near (UNVA), corrected distance (CDVA), and distance corrected near (DCNVA) visual acuity and manifest refraction were analyzed postoperatively.
RESULTS: At 1 year, the mean binocular UDVA improved significantly from 0.26 ± 0.25 to 0.039 ± 0.088 logMAR (P < .001). Binocular UNVA also improved from 0.73 ± 0.30 to 0.10 ± 0.22 logRAD (P < .001). Eighty-seven percent of patients achieved UDVA of 20/25 or better and 90% had UNVA of J3 or better. Simultaneous binocular distance and near vision of 20/25 and J2 or better was achieved in 70%. Only 17% of patients had a binocular DCNVA of J2 or better. No patient suffered from a loss of 2 lines of CDVA. Refractive stability was achieved for both eyes from 1 month postoperatively. The re-treatment rate was 14% for improvement of near vision within 6 months to 1 year.
CONCLUSIONS: Presbyopic correction using monocular PresbyMAX combined with monofocal regular LASIK in the fellow eye is safe and acceptable in hyperopic patients. [J Refract Surg. 2017;33(1):37-43.].
METHODS: In this retrospective case series, 36 consecutive patients (72 eyes) who underwent simultaneous bi-aspheric ablation (PresbyMAX: SCHWIND Eye-Tech-Solutions GmbH and Co KG, Kleinostheim, Germany) in the non-dominant eye and monofocal regular LASIK in the dominant eye for correction of hyperopia and presbyopia were reviewed for 1 year. Binocular uncorrected distance (UDVA), near (UNVA), corrected distance (CDVA), and distance corrected near (DCNVA) visual acuity and manifest refraction were analyzed postoperatively.
RESULTS: At 1 year, the mean binocular UDVA improved significantly from 0.26 ± 0.25 to 0.039 ± 0.088 logMAR (P < .001). Binocular UNVA also improved from 0.73 ± 0.30 to 0.10 ± 0.22 logRAD (P < .001). Eighty-seven percent of patients achieved UDVA of 20/25 or better and 90% had UNVA of J3 or better. Simultaneous binocular distance and near vision of 20/25 and J2 or better was achieved in 70%. Only 17% of patients had a binocular DCNVA of J2 or better. No patient suffered from a loss of 2 lines of CDVA. Refractive stability was achieved for both eyes from 1 month postoperatively. The re-treatment rate was 14% for improvement of near vision within 6 months to 1 year.
CONCLUSIONS: Presbyopic correction using monocular PresbyMAX combined with monofocal regular LASIK in the fellow eye is safe and acceptable in hyperopic patients. [J Refract Surg. 2017;33(1):37-43.].
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app